Literature DB >> 20224721

Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma.

Wei Li1, Dongfeng Tan, Maryam J Zenali, Robert E Brown.   

Abstract

Fibrolamellar hepatocellular carcinoma (FLHCC) is an aggressive neoplasm due to high frequency of recurrence after surgical resection and resistance to chemotherapy and radiation therapy. Activation of transcription factor NF-kB signaling pathway has been recognized for involvement in progression of various malignant neoplasms. The role of NF-kB pathway in FLHCC has not been studied to date. Formalin-fixed, paraffin-embedded tissue sections of 8 FLHCC, 10 normal liver tissues (NLT) were evaluated immunohistochemically for the expression of p-NF-kBp65 using phosphospecific antibody directed against phosphorylated (p)-NF-kBp65 (Ser 536). The level of p-NF-kBp65 (Ser 536) expression was categorized into four grades: 0 (background), 1+ (weak), 2+ (moderate), or 3+ (strong) based on intensity of intranuclear staining, and was further assessed using two scales: high expression (2+ or 3+) and low expression (0 or 1+). Only high expression of p-NF-kBp65 (Ser 536) in cells with nuclear translocation was considered as constitutive NF-kB activation. High expression of p-NF-kBp65 (Ser 536) was found in 88 % (7/8) of FLHCC tissue. In contrast, only 10 % (1/10) of NLT showed high expression for p-NF-kBp65 (Ser 536). The differences in p-NF-kBp65 nuclear expression between FLHCC tissue and NLT were significant (P < 0.001). There was no significant correlation between the expression of intranuclear p-NF-kBp65 and the stage of FLHCC. Constitutive NF-kB activation was observed in FLHCC. The findings suggest that NF-kB activation is involved in the tumorigenesis of FLHCC and may represent novel targets for therapeutic intervention to FLHCC.

Entities:  

Keywords:  Fibrolamellar hepatocellular carcinoma; immunohistochemistry; nuclear factor-kappa B

Mesh:

Substances:

Year:  2009        PMID: 20224721      PMCID: PMC2836501     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

1.  CT of fibrolamellar hepatocellular carcinoma.

Authors:  P Soyer; A Roche; M Levesque; P Legmann
Journal:  J Comput Assist Tomogr       Date:  1991 Jul-Aug       Impact factor: 1.826

2.  Fibrolamellar hepatocellular carcinoma. Therapeutic implications of a ten-year disease-free interval.

Authors:  P T Ang; H Evans; R Pazdur
Journal:  Am J Clin Oncol       Date:  1991-04       Impact factor: 2.339

3.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

4.  Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.

Authors:  H Nakshatri; P Bhat-Nakshatri; D A Martin; R J Goulet; G W Sledge
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

5.  TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB.

Authors:  C Y Wang; M W Mayo; A S Baldwin
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

6.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.

Authors:  M A Sovak; R E Bellas; D W Kim; G J Zanieski; A E Rogers; A M Traish; G E Sonenshein
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

7.  Fibrolamellar carcinoma of the liver--a case report.

Authors:  T Imai; H Yokoi; T Noguchi; Y Kawarada; R Mizumoto
Journal:  Gastroenterol Jpn       Date:  1991-06

8.  Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features.

Authors:  J R Craig; R L Peters; H A Edmondson; M Omata
Journal:  Cancer       Date:  1980-07-15       Impact factor: 6.860

Review 9.  Towards molecular diagnosis and targeted therapy of lymphoid malignancies.

Authors:  Adrian Wiestner; Louis M Staudt
Journal:  Semin Hematol       Date:  2003-10       Impact factor: 3.851

10.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Authors:  W Wang; J L Abbruzzese; D B Evans; L Larry; K R Cleary; P J Chiao
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

View more
  29 in total

1.  PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.

Authors:  Jennifer Stanley; Lisa Klepczyk; Kimberly Keene; Shi Wei; Yufeng Li; Andres Forero; William Grizzle; Monica Wielgos; Jason Brazelton; Albert F LoBuglio; Eddy S Yang
Journal:  Breast Cancer Res Treat       Date:  2015-04-02       Impact factor: 4.872

2.  A young woman with liver cancer.

Authors:  Celina S Ang; Richard K Do; Ali Shamseddine; Eileen M O'Reilly; Ali Haydar; Ashwaq Al-Olayan; Walid Faraj; Fouad Boulos; Mohamed Naghy; Dorothy Makanjoula; Hassan Farran; Hassan Sibai; David Wehbe; David P Kelsen; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

3.  Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.

Authors:  Elana P Simon; Catherine A Freije; Benjamin A Farber; Gadi Lalazar; David G Darcy; Joshua N Honeyman; Rachel Chiaroni-Clarke; Brian D Dill; Henrik Molina; Umesh K Bhanot; Michael P La Quaglia; Brad R Rosenberg; Sanford M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-21       Impact factor: 11.205

4.  Genomic analysis of fibrolamellar hepatocellular carcinoma.

Authors:  Lei Xu; Florette K Hazard; Anne-Flore Zmoos; Nadine Jahchan; Hassan Chaib; Phillip M Garfin; Arun Rangaswami; Michael P Snyder; Julien Sage
Journal:  Hum Mol Genet       Date:  2014-08-13       Impact factor: 6.150

5.  Molecular characteristics of fibrolamellar hepatocellular carcinoma.

Authors:  Attila Patonai; Boglárka Erdélyi-Belle; Anna Korompay; Aron Somorácz; Péter Törzsök; Ilona Kovalszky; Tamás Barbai; Erzsébet Rásó; Gábor Lotz; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2012-08-08       Impact factor: 3.201

6.  Cell cycle biology of fibrolamellar hepatocellular carcinoma.

Authors:  Sadhna Dhingra; Wei Li; Dongfeng Tan; Maryam Zenali; Haizeng Zhang; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-11-02

7.  Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB.

Authors:  Lida Zhang; Yangqiu Bai; Yuxiu Yang
Journal:  Oncol Lett       Date:  2016-08-08       Impact factor: 2.967

8.  The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma.

Authors:  Yi Jin; Jianning Chen; Zhiying Feng; Wenzhe Fan; Yu Wang; Jiaping Li; Dayue Tong
Journal:  Tumour Biol       Date:  2014-07-05

9.  Tanshinone IIA enhances chemosensitivity of colon cancer cells by suppressing nuclear factor-κB.

Authors:  Yangqiu Bai; Lida Zhang; Xinhui Fang; Yuxiu Yang
Journal:  Exp Ther Med       Date:  2016-01-12       Impact factor: 2.447

Review 10.  Modulation of apoptotic signaling by the hepatitis B virus X protein.

Authors:  Siddhartha Rawat; Amy J Clippinger; Michael J Bouchard
Journal:  Viruses       Date:  2012-11-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.